NEKTAR THERAPEUTICS
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $55.2 | $98.4 | $90.1 | $92.1 | $101.9 |
| Operating income | -$140.1 | -$105.2 | -$263.7 | -$376.2 | -$446.1 |
| Net income | -$164.1 | -$119.0 | -$276.1 | -$368.2 | -$523.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$208.7 | -$177.2 | -$193.5 | -$309.7 | -$427.6 |
| Share repurchases | $0.0 | $3.0 | $0.0 | — | — |
Shares outstanding 34.1M · Free float 27.9%
Annual filing data through FY ended December 31, 2025; float as of September 22, 2026.